PTCT PTC Therapeutics, Inc.

15.47
+0.11  (0.72%)
Previous Close 15.36
Open 15.44
Price To book 3.74
Market Cap 528.53M
Shares 34,165,000
Volume 560,035
Short Ratio 4.79
Av. Daily Volume 1,798,110

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515854
  2. S-8 - Securities to be offered to employees in employee benefit plans 17502613
  3. CT ORDER - Confidential treatment order 161993955
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161969237
  5. 8-K - Current report 161967886

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial to commence in 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest.
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 initiated July 2014. Enrolment completed November 2015. Data due late 1Q 2017.
Translarna
Nonsense mutation cystic fibrosis

Latest News

  1. European Commission Ratifies Positive CHMP Opinion for the Renewal of Translarna™ Marketing Authorization for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy
  2. PTC THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F
  3. PTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global Value of Translarna™ and Advance its Innovative Pipeline
  4. RG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy
  5. RG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy
  6. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  7. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  8. PTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients
  9. PTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients
  10. PTC Therapeutics to Present 2017 Corporate Update at the 35th Annual J.P. Morgan Healthcare Conference
  11. Are Options Traders Betting on a Big Move in PTC Therapeutics (PTCT) Stock?
  12. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  13. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  14. PTC Therapeutics Receives France's 2016 Prix Galien for Translarna™
  15. PTC Therapeutics, Inc. in 3 Charts
  16. Is PTC Therapeutics, Inc. (PTCT) a Good Stock to Buy?
  17. Why PTC Therapeutics, Inc. Stock Rose 75.4% in November
  18. Why Small Stocks Are Fueling Giant Returns
  19. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  20. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)